Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Blood (2023) 142 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2023-180809

Published: 2023

Journal Articles

Arsenic Trioxide Combine with G-CSF Triggers Distinct TP53 Mutations Acute Myeloid Leukemia Cells Ferroptosis through TP53-SLC7A11-GPX4 Pathway

Gelan Zhu, Wanbin Fu, Lan Xu, Yiwei Zhang, Jiong Hu, Jian Hou, Hua Zhong

Blood (2023) 142 (Supplement 1): 5989.

https://doi.org/10.1182/blood-2023-180676

Published: 2023

Journal Articles

Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia

Junyu Wang, Tuantuan Gui, Tong Yin, Yuting Dai, Jing Qiao, Jianfeng Li, Jie Xu, Yuanfang Liu, Yan Wang, Yun Tan, Bo Jiao, Yongmei Zhu, Zhu Chen, Wenlian Chen, Hai Fang, Jian Hou, Jian-Qing Mi, Jin Wang, Sai-Juan Chen

Blood (2023) 142 (Supplement 1): 2971.

https://doi.org/10.1182/blood-2023-184328

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2023-181063

Published: 2023

Journal Articles

Real-World Outcomes of Zanubrutinib Monotherapy in Chronic Lymphocytic Leukemia: A Multicenter Retrospective Study

Jing Luo, Jiaojiao Zhang, Ligen Liu, Rong Wei, Yonghua Yao, Min Xu, Jie Xu, Jumei Shi, Jianmin Yang, Jian Hou, Jin Wang, Jian-Qing Mi

Blood (2023) 142 (Supplement 1): 6540.

https://doi.org/10.1182/blood-2023-180477

Published: 2023

Journal Articles

Retrospective Analysis of Clinical Outcomes of Utilizing R-CHOP Plus Zanubrutinib for High-Risk Diffuse Large B Cell Lymphoma Patients with Extranodal Involvement or MYC/BCL2 Double Expression

Wanbin Fu, Jia Liu, Dan Xiao, Huanbin Zhao, Ting Wang, Jiong Hu, Jian Hou, Hua Zhong, Lan Xu

Blood (2023) 142 (Supplement 1): 6323.

https://doi.org/10.1182/blood-2023-182704

Published: 2023

Journal Articles

Epidemiological Features and Clinical Outcomes Predicting Risk and Prognosis of Transformed Marginal Zone Lymphoma: A SEER-Based Population Study

Minyue Zhang, Zihua Li, Fei Xiao, Jian Hou, Honghui Huang

Blood (2022) 140 (Supplement 1): 12002.

https://doi.org/10.1182/blood-2022-164472

Published: 2022

Journal Articles

NUP98-HOXA9 Bearing Acute Myeloid Leukemia

Yi Fang, Xiaofeng Han, Lijing Shen, Jian Hou

Blood (2022) 140 (Supplement 1): 11614.

https://doi.org/10.1182/blood-2022-167996

Published: 2022

Journal Articles

Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial

Wenjuan Yu, Hongsheng Zhou, Lijing Shen, Dong Chen, Xiang Zhang, Yanan Zhu, Xin Huang, Ying Lu, Jian Hou, Qifa Liu, Jie Jin

Blood (2022) 140 (Supplement 1): 3260–3261.

https://doi.org/10.1182/blood-2022-164933

Published: 2022

Journal Articles

Bortezomib-Decp Alternating with Daratumumab-Vpd Plus Stem Cell Transplantation, Followed By Maintenance with VP in Ultra-High Risk (UHiR) Newly Diagnosed Multiple Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): A Multicenter, Prospective Phase 2 Pilot Trial (DRAGON CATCHER TRIAL)

Jin Lu, Yang Liu, Jian Hou, Juan Li

Blood (2022) 140 (Supplement 1): 10189–10190.

https://doi.org/10.1182/blood-2022-164563

Published: 2022

Journal Articles

G-CSF Upregulates the Expression of Aquaporin-9 through C/EBP-Beta to Enhance the Cytotoxic Activity of Arsenic Trioxide to Acute Myeloid Leukemia Cells

Wanbin Fu, Lan Xu, Jia Liu, Xiaofeng Han, Junying Wang, Xinpeng Wang, Huanbin Zhao, Jian Hou, Jiong Hu, Hua Zhong

Blood (2021) 138 (Supplement 1): 4338.

https://doi.org/10.1182/blood-2021-149973

Published: 2021

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2021-146974

Published: 2021

Journal Articles

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2021-148937

Published: 2021

Journal Articles

Randomized Trial Comparing Pomalidomide, Bortezomib, and Dexamethasone (PVd) Versus Bortezomib and Dexamethasone（Vd） in NDMM with Renal Impairment（RI）

Jian Hou

Blood (2021) 138 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2021-146914

Published: 2021

Journal Articles

Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R 2 -chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma

Fei Xiao, Honghui Huang, PhD MD, Yanni Hua, Yi Fang, Minyue Zhang, Jian Hou, PhD MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141152

Published: 2020

Journal Articles

A Rare Aggressive Case of Follicular Dendritic Cell Sarcoma

Yi Fang, Fei Xiao, Jianchen Fang, Jian Hou, PhD MD, Honghui Huang, PhD MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-142259

Published: 2020

Journal Articles

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Haojie Jiang, Zhuo Yu, Nan Ding, Mina Yang, Lin Zhang, Xuemei Fan, Yuan Zhou, Qiang Zou, Jian Hou, Junke Zheng, Lei Zhang, Yanyan Xu, Junling Liu

Blood (2020) 136 (1): 119–129.

https://doi.org/10.1182/blood.2019003851

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Hong-Hui Huang, PhD MD, Jian Hou, PhD MD, Yang-Ming Zhang, PhD, Yu-Bo Zhou, PhD, Li Jia, PhD, Fa-Jun Nan, PhD

Blood (2019) 134 (Supplement_1): 5591.

https://doi.org/10.1182/blood-2019-129683

Published: 2019

Journal Articles

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Shuangshuang Yang, MD, Lijuan Chen, MD PhD, Jie Xu, MD PhD, Frank Xiao-Hu Fan, MD PhD, Sun Yan, PhD, Wen Wu, MD PhD, Yan Wang, MD, Jin Wang, MD PhD, Shiwei Jin, MD, Yuebo Zhou, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Wu Zhang, PhD, Jun-Min Li, Jian Hou, PhD MD, Jian-Yong Li, MD PhD, Zhu Chen, PhD, Jian-Qing Mi, MD PhD, Sai-Juan Chen, PhD

Blood (2019) 134 (Supplement_1): 5617.

https://doi.org/10.1182/blood-2019-131799

Published: 2019

NARROW

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Arsenic Trioxide Combine with G-CSF Triggers Distinct TP53 Mutations Acute Myeloid Leukemia Cells Ferroptosis through TP53-SLC7A11-GPX4 Pathway

Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Real-World Outcomes of Zanubrutinib Monotherapy in Chronic Lymphocytic Leukemia: A Multicenter Retrospective Study

Retrospective Analysis of Clinical Outcomes of Utilizing R-CHOP Plus Zanubrutinib for High-Risk Diffuse Large B Cell Lymphoma Patients with Extranodal Involvement or MYC/BCL2 Double Expression

Epidemiological Features and Clinical Outcomes Predicting Risk and Prognosis of Transformed Marginal Zone Lymphoma: A SEER-Based Population Study

NUP98-HOXA9 Bearing Acute Myeloid Leukemia

Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial

Bortezomib-Decp Alternating with Daratumumab-Vpd Plus Stem Cell Transplantation, Followed By Maintenance with VP in Ultra-High Risk (UHiR) Newly Diagnosed Multiple Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): A Multicenter, Prospective Phase 2 Pilot Trial (DRAGON CATCHER TRIAL)

G-CSF Upregulates the Expression of Aquaporin-9 through C/EBP-Beta to Enhance the Cytotoxic Activity of Arsenic Trioxide to Acute Myeloid Leukemia Cells

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Randomized Trial Comparing Pomalidomide, Bortezomib, and Dexamethasone (PVd) Versus Bortezomib and Dexamethasone（Vd） in NDMM with Renal Impairment（RI）

Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R 2 -chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma

A Rare Aggressive Case of Follicular Dendritic Cell Sarcoma

The role of AGK in thrombocytopoiesis and possible therapeutic strategies

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only